secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010978
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma reports FY2022 revenue $67.8M, cash runway into H2 2024; plans luvelta Phase 2/3 in Q2 2023
--------------------------------------------------------------------------------

- Cash and investments of $302.3M plus Vaxcyte stock valued at $32.0M provide cash runway into H2 2024.
- Revenue for FY2022 was $67.8M, up from $61.9M in FY2021, driven by collaboration payments.
- Total operating expenses were $196.7M, up from $160.4M, with R&D at $137.2M and G&A at $59.5M.
- Plans to initiate Phase 2/3 registration-directed study of luvelta in platinum-resistant ovarian cancer in Q2 2023.
- Dr. Anne Borgman appointed Chief Medical Officer in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/stro-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer